Ifetroban

Phase 2Small molecule

CCumberland Pharmaceuticals

Ifetroban is one of 2 small molecule programs targeting Scleroderma, Diffuse. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Scleroderma, DiffuseActive, not recruiting

Scleroderma, DiffusePhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Scleroderma, Diffuse

#DrugCompanyPhaseTrials

Rapcabtagene Autoleucel

Novartis

Phase 2

1 2

Ifetroban

CCumberland Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Disease3 trials

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

Completed·—·Phase 2·NCT03326063·38 enrolled

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

Completed·CCumberland Pharmaceuticals·Phase 2·NCT02216357·19 enrolled

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

Completed·CCumberland Pharmaceuticals·Phase 2·NCT03028350·54 enrolled

Duchenne Muscular Dystrophy1 trial

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Completed·CCumberland Pharmaceuticals·Phase 2·NCT03340675·46 enrolled

Hepatorenal Syndrome1 trial

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Completed·CCumberland Pharmaceuticals·Phase 2·NCT01436500·55 enrolled

Portal Hypertension1 trial

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Completed·CCumberland Pharmaceuticals·Phase 2·NCT02802228·30 enrolled

Scleroderma, Diffuse1 trial

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)

Active, not recruiting·CCumberland Pharmaceuticals·Phase 2·NCT02682511·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ifetroban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ifetroban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ifetroban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cumberland Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCumberland Pharmaceuticals

Ifetroban

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Disease3 trials

Duchenne Muscular Dystrophy1 trial

Hepatorenal Syndrome1 trial

Portal Hypertension1 trial

Scleroderma, Diffuse1 trial

References

Drug Info

Quick Facts

Related News